Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.